The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d

Henry S. Sacks

2021Annals of Internal Medicine10 citationsDOI

Abstract

SOURCE CITATION: N Engl J Med. 2021. [Epub ahead of print.] 33882225.

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyCoronavirus InfectionsInternal medicinePharmacologyOutbreakDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchHepatitis B Virus StudiesImmunotherapy and Immune Responses

The single-dose J&amp;J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d

Abstract

Topics & Concepts

The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d